London School of Hygiene & Tropical Medicine, Keppel Street, London, WC1E 7HT, UK.
Kenya Medical Training College, Nairobi, Kenya.
Syst Rev. 2021 Jan 14;10(1):27. doi: 10.1186/s13643-020-01562-9.
Vision loss due to diabetic retinopathy can largely be prevented or delayed through treatment. Patients with vision-threatening diabetic retinopathy are typically offered laser or intravitreal injections which often require more than one treatment cycle. However, treatment is not always initiated, or it is not completed, resulting in poor visual outcomes. Interventions aimed at improving the uptake or completion of treatment for diabetic retinopathy can potentially help prevent or delay visual loss in people with diabetes.
We will search MEDLINE, Embase, Global Health and Cochrane Register of Studies for studies reporting interventions to improve the uptake of treatment for diabetic retinopathy (DR) and/or diabetic macular oedema (DMO), compared with usual care, in adults with diabetes. The review will include studies published in the last 20 years in the English language. We will include any study design that measured any of the following outcomes in relation to treatment uptake and completion for DR and/or DMO: (1) proportion of patients initiating treatment for DR and/or DMO among those to whom it is recommended, (2) proportion of patients completing treatment for DR and/or DMO among those to whom it is recommended, (3) proportion of patients completing treatment for DR and/or DMO among those initiating treatment and (4) number and proportion of DR and/or DMO rounds of treatment completed per patient, as dictated by the treatment protocol. For included studies, we will also report any measures of cost-effectiveness when available. Two reviewers will screen search results independently. Risk of bias assessment will be done by two reviewers, and data extraction will be done by one reviewer with verification of 10% of the papers by a second reviewer. The results will be synthesised narratively.
This rapid review aims to identify and synthesise the peer-reviewed literature on the effectiveness of interventions to increase uptake and completion of treatment for DR and/or DMO in LMICs. The rapid review methodology was chosen in order to rapidly synthesise the available evidence to support programme implementers and policy-makers in designing evidence-based health programmes and public health policy and inform the allocation of resources.
OSF osf.io/h5wgr.
糖尿病视网膜病变导致的视力丧失在很大程度上可以通过治疗来预防或延缓。对于有威胁视力的糖尿病性视网膜病变患者，通常会提供激光或眼内注射治疗，这些治疗往往需要多个治疗周期。然而，治疗并非总是开始，或者治疗未完成，导致视力结果不佳。旨在提高糖尿病视网膜病变治疗接受度或完成度的干预措施可能有助于预防或延缓糖尿病患者的视力丧失。
我们将检索 MEDLINE、Embase、全球卫生和 Cochrane 研究注册库，以寻找与常规护理相比，用于提高糖尿病患者糖尿病视网膜病变（DR）和/或糖尿病黄斑水肿（DMO）治疗接受度和完成度的干预措施的研究报告。综述将包括过去 20 年用英语发表的研究。我们将纳入任何研究设计，这些研究设计测量了与 DR 和/或 DMO 治疗接受度和完成度相关的以下结果：（1）建议治疗的 DR 和/或 DMO 患者中开始治疗的患者比例，（2）建议治疗的 DR 和/或 DMO 患者中完成治疗的患者比例，（3）开始治疗的患者中完成治疗的患者比例，以及（4）根据治疗方案规定，每位患者完成的 DR 和/或 DMO 治疗轮次的数量和比例。对于纳入的研究，我们还将报告任何成本效益措施。两位审查员将独立筛选搜索结果。两位审查员将进行偏倚风险评估，一位审查员将进行数据提取，并由第二位审查员验证 10%的论文。结果将以叙述性方式进行综合。
本快速综述旨在确定和综合中低收入国家提高 DR 和/或 DMO 治疗接受度和完成度的干预措施的同行评议文献。选择快速综述方法是为了快速综合现有证据，以支持方案实施者和政策制定者设计基于证据的卫生方案和公共卫生政策，并为资源分配提供信息。
OSF osf.io/h5wgr。
